Online Disruptive 10-Q 25 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 25, 2019
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Entity Registrant Name	ONLINE DISRUPTIVE TECHNOLOGIES, INC.
Entity Central Index Key	0001498380
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		132,300,587
Entity Current Reporting Status	Yes
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false

Condensed Interim Consolidated

Condensed Interim Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets
Cash and Cash Equivalents	$ 197,180	$ 120,245
Restricted Cash	31,262	29,185
Prepaid Expenses	11,351	23,467
VAT Receivable	17,858	20,141
Total Current Assets	257,651	193,038
Fixed Assets	35,629	45,274
Right-of-use Assets	69,505
Total Assets	362,785	238,312
Current Liabilities
Accounts Payable	225,076	194,400
Accrued Liabilities	264,099	196,316
Promissory Note	18,208	50,000
Current Portion of Lease Liability	55,700
Total Current Liabilities	563,083	440,716
Convertible Debentures	2,061,388	2,061,388
Convertible Loans	616,736	537,000
Lease Liabilities	15,594
Total Liabilities	3,256,801	3,039,104
DEFICIT
Authorized: 20,000,000 Preferred Shares, par value $0.001 500,000,000 Common Shares, par value $0.001 Issued and outstanding: Nil Preferred Shares 127,240,587 Common Shares (December 31, 2018: 124,063,122 Common Shares)	127,241	124,063
Shares Subscription Received	936,000
Additional Paid-in Capital	13,241,765	12,340,094
Accumulated Other Comprehensive Loss	(52,675)	80,946
Deficit	(16,884,830)	(15,255,866)
Deficit Attributable to Shareholders of the Company	(2,632,499)	(2,710,763)
Non-Controlling Interests	(261,517)	(90,029)
Total Deficit	(2,894,016)	(2,800,792)
Total Liabilities and Deficit	$ 362,785	$ 238,312

Condensed Interim Consolidate_2

Condensed Interim Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Par Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Issued	127,240,587	124,063,122
Common Stock, Shares, Outstanding	127,240,587	124,063,122

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
General and Administrative Expenses
Accounting Fees	$ 7,500	$ 7,500	$ 22,500	$ 22,500
Audit & Tax Fees	20,595	10,019	61,228	82,465
Bank Fees	155	113	567	478
Consulting Fees	182,895	92,381	366,412	296,184
Lease Expense	9,198	0	26,662
Filing and Transfer Agent Fees	27	2,618	8,653	6,484
Insurance Expense	1,306	10,823	9,626	25,337
Marketing Expense	1,155		5,574
Legal Fees	5,216	6,808	13,956	16,852
Office and Miscellaneous Expense	1,323	15,529	7,467	20,443
Payroll Expense	9,213	8,852	27,149	27,312
Research and Development Expense	406,664	449,188	1,193,917	1,853,950
Travel Expenses	13,915	1,286	24,186	8,621
Total General and Administrative Expense	659,162	605,117	1,767,897	2,360,626
Other Expense
Lease Liability Expense	975		3,318
Fair Value through Profit and Loss on Loan		25,698		42,976
Interest Accretion		5,535		154,097
Interest Expense	14,785	23,602	83,554	23,704
Foreign Currency (Gain) Loss	1,023	(65,713)	(67,189)	6
Net Loss for the period	(675,945)	(594,239)	(1,787,580)	(2,581,409)
Other Comprehensive Income
Currency Translation Adjustments	(38,657)	(53,665)	(133,622)	2,861
Comprehensive Loss for the period	(714,602)	(647,904)	(1,921,202)	(2,578,548)
Net Loss attributable to:
Common Stockholders	(619,116)	(535,865)	(1,628,964)	(2,321,190)
Non-Controlling Interests	(56,829)	(58,374)	(158,616)	(260,219)
Net Loss for the period	(675,945)	(594,239)	(1,787,580)	(2,581,409)
Net Comprehensive Loss Attributable to:
Common Stockholders	(654,614)	(582,592)	(1,750,731)	(2,318,618)
Non-Controlling Interests	(59,988)	(65,312)	(170,471)	(259,930)
Comprehensive (Loss) for the Period	$ (714,602)	$ (647,904)	$ (1,921,202)	$ (2,578,548)
Basic and Diluted Net Loss per Common Share	$ 0	$ 0	$ (0.01)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	127,240,587	121,619,939	126,340,628	120,136,973

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flow from Operating Activities
Net loss for the period	$ (1,787,580)	$ (2,581,409)
Adjustment for items not involving cash:
Lease expense	29,980
Stock-based compensation	538,054	1,184,096
Foreign exchange (gain) loss	(67,189)	6
Fair value through profit and loss on loan		42,976
Depreciation - fixed assets	12,821	11,241
Interest accretion	83,554	154,097
Changes in non-cash working capital items:
Decrease(Increase) in VAT receivable	2,283	(508)
Decrease in prepaid expense	12,116	12,372
(Decrease) Increase in accounts payable and accrued liabilities	(98,459)	237,904
Net cash used in operating activities	(1,274,420)	(939,225)
Cash flow from financing activities
Common shares issued, net of issuance costs	449,654	476,145
Share subscription received	926,000
Convertible loan issued		537,000
Term loan repayment	(35,000)
Net cash provided by financing activities	1,340,654	1,013,145
Cash flow from investing activities
Cash utilized in purchase of assets		(5,152)
Net cash used in investing activities	0	(5,152)
Effects of exchange rate changes on cash and cash equivalents	12,778	4,023
Net increase in cash and cash equivalents	79,012	72,791
Cash and cash equivalents, beginning of period	120,245	232,247
Restricted cash, beginning of period	29,185
Cash and cash equivalents, end of period	197,180	305,038
Restricted cash, end of period	31,262
Supplementary Information
Interest Paid	0	0
Income Taxes Paid	$ 0	$ 0

Nature of Operations and Going

Nature of Operations and Going Concern	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Nature of Operations and Going Concern [Text Block]	Note 1 - Nature of Operations and Going Concern Online Disruptive Technologies, Inc. ("ODT" or the "Company") was incorporated on November 16, 2009 in the State of Nevada, U.S.A. The Company was in the business of operating websites with advertising revenue platforms. However, as described below, the Company changed its primary business focus to the development and commercialization of a biotechnology platform. The Company has limited operations that has had no revenues from inception to date. The Company has a December 31 year-end. Effective March 24, 2010, the Company acquired 100% of the issued and outstanding shares of RelationshipScoreboard.com Entertainment Inc. (“RS” or “RelationshipScoreboard.com”), a company incorporated on November 16, 2009 in the state of Nevada, U.S.A. in exchange for 16,000,000 shares of the Company's common stock. Upon the completion of the acquisition, the former sole shareholder of RS held 89% of the Company’s issued and outstanding common stock. As a result, the transaction was accounted for as a reverse takeover transaction (“RTO”) for accounting purpose, as RS was deemed to be the acquirer, and these condensed interim consolidated financial statements are a continuation of the financial statements of RS. On January 28, 2013, RelationshipScoreboard.com was closed and dissolved. The Company sold the website assets for $10 to an arm’s length individual and wrote off all supplier payables in the amount of $430. On April 23, 2012, the Company established an Israeli subsidiary named Savicell Diagnostic Ltd. ("Savicell") with the intention of exploring business ventures in the biotechnology sector. On July 25, 2012, Savicell entered into a definitive licensing agreement with a division of the Tel Aviv University for the purpose of developing and commercializing a new technology relative to the early detection of various forms of disease. With the consummation of this transaction, the Company is now entirely focused on its biotechnology efforts. These condensed interim consolidated financial statements have been prepared with the ongoing assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has a working capital deficit balance of $305,432 as at (working capital deficit balance December 31, 2018 – $247,678) and an accumulated deficit of $16,884,830. The operations of the Company have primarily been funded by the sale of common shares and loans received. Continued operations of the Company are dependent on the Company's ability to complete equity financings or to generate profitable operations in the future. Management's plan in this regard is to secure additional funds through future equity financings. Such financings may not be available or may not be available on reasonable terms to the Company. Failure to obtain the ongoing support of its equity financings and creditors may make the going concern basis of accounting inappropriate, in which case the Company's assets and liabilities would need to be recognized at their liquidation values. These condensed interim consolidation financial statements do not include any adjustments relating to the recoverability and classification of recorded assets amounts and classification of liabilities that might arise from this uncertainty. The information included in these condensed interim consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes filed in Form 10-K for the year ended December 31, 2018 filed on April 03, 2019 with the U.S. Securities and Exchange Commission.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Significant Accounting Policies [Text Block]	Note 2 - Significant Accounting Policies a) Basis of Presentation These condensed interim consolidated financial statements have been prepared for interim financial reporting in conformity with generally accepted accounting principles in the United States of America ("US GAAP"), and are expressed in United States dollars, unless otherwise noted. All adjustments considered necessary for a fair presentation of financial position, results of operations and cash flows for the nine months ended September 30, 2019 have been included. b) Principles of Consolidation These condensed interim consolidated financial statements include the accounts of the Company and its 87.87% (December 31, 2018 – 87.81%) interest in Savicell. All significant intercompany accounts and transactions have been eliminated upon consolidation. c) Use of Estimates The preparation of condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred tax assets and assessment of lease. d) Foreign Currency Translation The Company’s functional currency is the U.S. dollar. The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). Transactions in other currencies are recorded in U.S. dollars at the rates of exchange prevailing when the transactions occur. Monetary assets and liabilities denominated in other currencies are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates. Exchange gains and losses are recorded in the statements of operations. Results of operations are translated into the Company’s presentation currency, U.S. dollars, at an appropriate average rate of exchange during the year. Net assets and liabilities are translated to U.S. dollars for presentation purposes at rates of exchange in effect at the end of the period. Gains or losses arising on translation are recognized in other comprehensive income (loss) as foreign currency translation adjustments. e) Cash and Cash Equivalents Cash and cash equivalents consist entirely of readily available cash balances. There were no cash equivalents as of September 30, 2019 and December 31, 2018. f) Restricted cash Restricted cash mainly consists of cash reserve and security deposits required for rental office. g) Stock-based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation-Stock Compensation ("ASC 718"). ASC 718 requires all stock-based payments to employees and non-employees including grants of stock options, to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. h) Stock for Services The Company periodically issues common stock, warrants and common stock options to consultants for various services. Costs of these transactions are measured at the fair value of the service received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. i) Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, deferred tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply when the asset is realized or the liability is settled. The effect of a change in income tax rates on deferred tax liabilities and assets is recognized in income in the period in which the change occurs. Deferred tax assets are recognized to the extent that they are considered more likely than not to be realized. Per FASB ASC 740 "Income taxes" under the liability method, it is the Company's policy to provide for uncertain tax positions and the related interest and penalties based upon management's assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At September 30, 2019, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company's effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company's tax positions are recorded as Interest Expense. j) Comprehensive Income (Loss) The Company accounts for comprehensive income under the provisions of ASC Topic 220-10, Comprehensive Income - Overall, which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statements of Operations and Comprehensive Loss. k) Earnings (Loss) Per Share Basic loss per share is computed on the basis of the weighted average number of common shares outstanding during each period. Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the three and nine months ended September 30, 2019 and 2018 because the inclusion of such underlying shares would have had an anti-dilutive effect. l) Financial Instruments and Fair Value of Financial Instruments Fair Value of Financial Instruments - the Company adopted SFAS ASC 820-10-50, "Fair Value Measurements". This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: • Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. • Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at September 30, 2019, the fair value of cash and cash equivalents was measured using Level 1 inputs, and the fair value of convertible debentures was measured using Level 2 inputs. The Company's financial instruments are cash and cash equivalents, restricted cash, accounts payable, accrued liabilities, promissory note, convertible debentures and convertible loans. The recorded values of our financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. m) Research and Development Expenses In the quarter ended September 30, 2019, all research and development costs are charged to expense as incurred. The majority of these costs are in-house expenses related to consulting fees, materials, salaries of employees working on the R&D projects, rent and legal expenses related to patents. A breakdown of the R&D costs is as follows: Nine months Nine months Three months Three months ended September 30, ended September 30, ended September 30, ended September 30, 2019 2018 2019 2018 Research and Development $ $ $ $ Expenses Consulting fees 35,648 20,069 11,839 5,169 Legal fees 17,918 12,993 4,083 4,686 Office and Miscellaneous Expense 5,549 10,390 1,374 3,444 Payroll expense 533,381 578,825 220,466 191,187 R&D materials and supplies 59,076 20,348 16,211 4,022 Rent 4,291 27,229 2,254 9,732 Share-based compensation 538,054 1,184,096 150,437 230,948 Total 1,193,917 1,853,950 406,664 449,188 Savicell’s financing commitment related to the License and Research Funding Agreement (as defined in Note 4 below) entered into with Ramot at Tel Aviv University was completely fulfilled by December 31, 2015. n) Fixed Assets The depreciation rates applicable to each category of fixed assets are as follows: Class of Properties Depreciation Rate Furniture and Fixtures 15-year; straight-line basis Computer Equipment 3 to 4-year; straight-line basis Lab Equipment 3 to 15-year; straight-line basis o) Convertible Debentures p) Convertible Loans Convertible loans are accounted for in accordance with ASC 470-20. The Company has determined that the embedded conversion options in the convertible loans are not required to be separately accounted for as a derivative under GAAP. q) Modifications to Debt The Company evaluates any modifications to its debt in accordance with the applicable guidance in ASC 470-50, Debt-Modifications and Extinguishments. If the debt instruments are substantially modified, the modification is accounted for in the same manner as a debt extinguishment (i.e., a major modification) and the fees paid are recognized as expense at the time of the modification. Otherwise, such fees are deferred and amortized as an adjustment of interest expense over the remaining term of the modified debt instrument using the interest method. r) Recently Adopted Accounting Pronouncements In July 2017, the FASB issued ASU 2017-11“Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception” (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered, and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to Common Stock holders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company has early adopted the methodologies prescribed by this ASU for the year ended December 31, 2018 and there is no material impact on the Company’s condensed interim consolidated financial statements. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases. For entities that early adopted Topic 842, the amendments are effective upon issuance of ASU 2018-10, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. ASU 2018-10 will be effective for use for fiscal years beginning after December 15, 2018. The Company has adopted the methodologies prescribed by this ASU on January 1, 2019 and there is no material impact on the Company’s condensed interim consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. These amendments expand the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Non-Employees. This standard is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company has adopted the methodologies prescribed by this ASU on January 1, 2019 and there is no material impact on the Company’s condensed interim consolidated financial statements. In February 2016, the Financial Accounting Standards Board ("FASB") issued ASC 842 which requires lessees to recognize a right-of-use ("ROU") asset and lease liability on the balance sheet for virtually all leases. From a lessee perspective, ASC 842 retains a dual model requiring leases to be classified as either operating or finance leases for the income statement. Operating leases will result in straight-line expense, and financing leases will have a front-loaded expense pattern with an interest expense component. On January 1, 2019, the Company adopted ASC 842 and all related amendments using the prospective transition approach. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. Adoption of the new standard resulted in the recording of lease ROU assets and lease liabilities of approximately $90,146 as of January 1, 2019. s) Recently Issued Accounting Pronouncements Not Yet Adopted In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. For all entities, amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact this guidance will have on the condensed interim consolidated financial statements, if any.

Adoption of ASC 842, Leases

Adoption of ASC 842, Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Adoption of ASC 842, Leases [Text Block]	Note 3 – Adoption of ASC 842, Leases On January 1, 2019, the Company adopted ASC 842 using the prospective transition approach, which applies the provisions of the new guidance at the effective date without adjusting the comparative periods presented. The adoption of the lease standard did not result in a cumulative-effect adjustment to opening equity. Results for reporting periods beginning after January 1, 2019 are presented under ASC 842 while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC 840, “Leases,” (“ASC 840”). The Company leases office space. For leases with terms greater than 12 months, the Company records the related right-of-use ("ROU") asset and lease obligation at the present value of lease payments over the term. Leases may include fixed rental escalation clauses, renewal options and / or termination options that are factored into the determination of lease payments when appropriate. The Company's leases do not usually provide a readily determinable implicit rate; therefore, an estimate of the Company's incremental borrowing rate is used to discount the lease payments based on information available at the lease commencement date. The discount rate used was 5%. Operating lease costs during the three and nine months ended September 30, 2019 were The adoption of ASC 842 resulted in the recognition of ROU assets and lease liabilities of approximately $90,146 as of January 1, 2019. As at September 30, 2019, ROU Asset is $69,505, current portion and long term portion of these lease liabilities are $55,700 and $15,594 respectively. The standard did not materially impact the Company’s condensed interim consolidated statement of operations or its condensed interim consolidated statement of cash flows . See below for the Company’s updated lease policy and the required disclosures under ASC 842. The Company is a lessee in a rental lease that has expiry dates within the next 2 years. Right-of-use Asset Lease Liability $ $ Balance, December 31, 2018 — — Adoption of ASC 842 90,146 103,917 Lease expense (26,662 ) — Lease liability expense — 3,318 Lease payments — (42,620 ) Effect of foreign exchange rate changes 6,021 6,679 Balance, September 30, 2019 69,505 71,294 Current — 55,700 Non-current — 15,594 The Company is a lessee in two leases that have expiry dates ranging between two (2) and three (3) years. The table below summarizes the remaining expected lease payments under our operating leases as of September 30, 2019. Future Lease Payments September 30, 2019 2019 $ 14,207 2020 45,724 2021 11,759 Less: imputed interest (396 ) Present value of operating lease liabilities $ 71,294 Update to Lease Policy Accounting and reporting guidance for leases requires that leases be evaluated and classified as either operating or finance leases by the lessee and as either operating, sales-type or direct financing leases by the lessor. The Company’s operating leases are included in ROU assets, lease liabilities-current portion and lease liability-less current portion in the accompanying consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease.

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Fixed Assets [Text Block]	Note 4 – Fixed Assets As of September 30, 2019, the fixed assets balance on the consolidated financial statement consist of the following: Furniture and Computer Cost: Fixtures Equipment Lab Equipment Total December 31, 2017 $ 3,871 $ 29,325 $ 49,191 $ 82,387 Additions — 9,933 10,897 20,830 Exchange difference (286 ) (2,580 ) (4,089 ) (6,955 ) December 31, 2018 $ 3,585 $ 36,678 $ 55,999 $ 96,262 Additions — — — — Exchange difference 274 2,802 4,278 7,354 September 30, 2019 $ 3,859 $ 39,480 $ 60,277 $ 103,616 Furniture and Computer Lab Amortization: Fixtures Equipment Equipment Total December 31, 2017 $ 887 $ 19,497 $ 14,868 $ 35,252 Additions 137 6,692 12,311 19,140 Exchange difference (65 ) (1,440 ) (1,899 ) (3,404 ) December 31, 2018 $ 959 $ 24,749 $ 25,280 $ 50,988 Additions 208 3,327 9,286 12,821 Exchange difference ( 615 ) ( 10,289 ) 15,082 4,178 September 30, 2019 $ 552 $ 17,787 $ 49,648 $ 67,987 Furniture and Computer Lab Net Book Value: Fixtures Equipment Equipment Total December 31, 2018 $ 2,626 $ 11,929 $ 30,719 $ 45,274 September 30, 2019 $ 3,307 $ 21,693 $ 10,629 $ 35,629 The Company recorded depreciation in R&D materials and supplies in Research and Development expenses as disclosed in Note 2 (l).

License and Research Funding Ag

License and Research Funding Agreement	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
License and Research Funding Agreement [Text Block]	Note 5 – License and Research Funding Agreement On July 25, 2012, the Company’s subsidiary Savicell entered into a License and Research Funding Agreement (“R&D Agreement”) with Ramot at Tel Aviv University (“Ramot”) pursuant to which: In the course of research performed at Tel-Aviv University (" TAU Savicell wishes to fund further research at TAU relating to such technology; and Savicell wishes to obtain a license from Ramot with respect to such technology and the results of such further funded research in order to develop and commercialize products in the diagnostics space, and Ramot wishes to grant the Company such license, all in accordance with the terms and conditions of this R&D Agreement. Pursuant to the above noted R&D Agreement, Savicell funded research expenditures amounting to a total of $1,600,000 (paid in prior years). $81,000 within 5 business days of the R&D Agreement (paid) Before October 2012; $359,500 plus VAT as applicable (paid) Before January 3, 2013; $359,500 plus VAT as applicable (paid) Before April 3, 2013; $400,000 plus VAT as applicable (paid) The payments originally due on April 3, 2013 and July 3, 2013 were postponed by the parties until such time as the funds were actually required in furtherance of the joint research and development initiatives. As of December 31, 2015, Savicell’s entire financing commitment has been met and no more expenditures are mandated by the R&D Agreement on behalf of Ramot. Savicell is continuing the clinical research within its own laboratory situated in Haifa, Israel. In addition, during fiscal year 2013, Savicell agreed to issue to Ramot warrants (the “Warrants”) to purchase a number of ordinary shares of Savicell which shall together comprise 15% of issued shares of Savicell on an as-converted, fully diluted basis (equivalent to 1,765 Warrant Shares of Savicell). The Warrants shall be exercisable at an exercise price equal to the par value of the Warrant Shares, at any time and from time to time before Savicell completes a deemed liquidity event or the first underwritten offering of the Savicell's ordinary shares to the general public. The fair value of the Warrant Shares has been estimated at $1,698.97 per Warrant Share which is equivalent to the price at which Savicell has issued shares to third parties, for a total of $2,998,682 which has been included in research and development costs. As the exercise price inherent in the warrant certificate to purchase 1,765 common Upon successful development and commercialization of the technology, and in recognition of the rights and licenses granted to Savicell pursuant to this R&D Agreement, Savicell will be subject to (a) royalties based on the worldwide sales related to the technology; and (b) minimum annual royalties with respect to any calendar year following the first commercial sales as follows. The minimum annual royalties are subject to increases for each successive year. During the three and nine months ended September 30, 2019, Savicell incurred research and development costs of $406,664 and $1,193,917 respectively ( $449,188 and $1,853,950)

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Related Party Transactions [Text Block]	Note 6 – Related Party Transactions The Company completed the following related party transactions: During the three and nine months ended September 30, 2019, the Company incurred consulting fees and salaries of $128,703 and $385,649 ( - $98,644 and $364,132) payable to its directors and officers. As at September 30, 2019, there was $220,020 ( ) payable to current officers and directors of the Company. As at September 30, 2019, included in convertible debentures are amounts of $2,061,388 (December 31, 2018 - $2,061,388) that was entered into with two directors, one consultant, and one key management personnel of the Company (Note 8).

Promissory Note

Promissory Note	9 Months Ended
	Sep. 30, 2019
Notes Payable [Abstract]
Promissory Note [Text Block]	Note 7 – Promissory Note During the year ended December 31, 2018, the Company issued a promissory note to the spouse of a consultant and former director of the Company for $50,000. The note bears interest at the rate of 10% per annum with an initial maturity date of the earlier of February 28, 2019 or the closing by the Company of an equity financing of at least $250,000. is $663 and $2,865 ( nil ). During the nine months ended the Company has repaid $35,000. The remaining balance is due on demand and the parties have agreed to allow for ultimate repayment beyond the originally contemplated maturity date.

Convertible Debentures

Convertible Debentures	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Convertible Debentures [Text Block]	Note 8 – Convertible Debentures On April 15, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $852,418. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.055 over a seven year term. On December 31, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $188,085 with an unsecured and non-interest bearing convertible debenture. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a seven year term. On December 31, 2016, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $172,895 Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a seven-year term. On December 31, 2018, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $843,266 Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a ten-year term. The Company evaluated these convertible debentures for derivatives and determined that they do not qualify for derivative treatment. The Company then evaluated the debenture for beneficial conversion features and determined that the convertible debenture issued on April 15, 2015 does contain beneficial conversion features. The aggregate intrinsic value of the beneficial conversion features was determined to be $852,418. This amount was recorded as a debt discount on April 15, 2015 that is being amortized over the life of the debenture at effective interest rate of 71%. The total debt discount amortization of $852,418 was fully recognised as of December 31, 2018. December 31, 2018 Additions September 30, 2019 Giora Davidovits $ 860,293 $ — $ 860,293 Eyal Davidovits 402,861 — 402,861 Irit Arbel 355,746 — 355,746 Robbie Manis 437,763 — 437,763 Total $ 2,056,663 $ — $ 2,056,663 December 31, 2018 Additions September 30, 2019 Convertible debentures $ 2,056,663 $ — $ 2,056,663 Convertible discount (852,418 ) — (852,418 ) Net convertible debentures 1,204,245 — 1,204,245 Interest accretion 852,418 — 852,418 Exchange difference 4,725 — 4,725 Balance $ 2,061,388 $ — $ 2,061,388

Convertible Loans

Convertible Loans	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Convertible Loans [Text Block]	Note 9 – Convertible Loan On March 8, 2018, the Company issued one convertible loan in the face amount of $350,000 to two current shareholders. The convertible loan matures after two years and bears interest at a rate of 10% per annum. The convertible loan may be converted into common shares of the Company at the earlier of fifteen days after the maturity date and the date the Company raises gross proceeds of $5,000,000 through private placements or files a registration statement with the Securities and Exchange Commission in the United States. The conversion price is $0.20 per share or such lesser price that the Company may issue additional shares to third parties, and, on conversion or repayment of the convertible loan, the Company will issue warrants in a number that is equal to the amount of the loan divided by the conversion price, exercisable at the funding price. In addition, the Company will reset the prior investment price issuable to each Lender for the amount equal to the lower of the prior investment made by such lenders and the amount invested by such lenders under this loan agreement. Such lower amount is referred to as “ Covered Investment”. The incremental number of common shares to be issued to the lenders by the Company is the Covered Investment divided by the reduced share price less the number of common shares previously issued by the Company in respect of the Covered Investment. During the year ended December 31, 2018, the Company issued four convertible loans in the aggregate amount of $187,000 to four individual lenders. The debentures are interest bearing at a rate of 10% per annum and have a term to maturity of two years. The loans are convertible into common shares of the Company at the lower of $0.20 per share and the price of a future financing initiative. Moreover, warrants will be granted to the lenders upon the earlier of repayment of the loans or conversion thereof, in a number that is equal to the amount of the convertible loans divided by the conversion price, exercisable at the funding price. The Company evaluated these convertible loans for derivatives and determined that they do not qualify for derivative treatment. Interest will be accrued and be due and payable upon the maturity date of the loan. The accrued interest will also be converted into common shares of the company. Interest incurred is $ and $79,736 nil

Equity

Equity	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Equity [Text Block]	Note 10 – Equity Common Shares On April 17, 2018, stock options previously granted by the Company were exercised, resulting in the issuance of 481,179 common shares at $0.01 per share for total proceeds of $4,812. On June 20, 2018, the Company issued 117,660 shares at $0.20 per share for an aggregate amount of $23,532 in exchange for consulting services rendered during the year ended December 31, 2018. On August 24, 2018, the Company issued 16,665 common shares at $0.20 per share for total proceeds of $3,333 for stock options that were exercised during the year ended December 31, 2018. On August 27, 2018, stock options previously granted by the Company to a consultant were exercised resulting in the issuance of 800,000 common shares at $0.01 per share. The Company will receive consulting services from this consultant in 2019 in lieu of receiving cash proceeds from this issuance. On September 7, 2018, the Company issued an aggregate of 2,300,000 units at a price of $0.20 per unit for gross proceeds of $460,000. Each unit is comprised of one common share of the Company and one non-transferable common share purchase warrant with each warrant being exercisable into one additional share at an exercise price of $0.20 per warrant share for a period of two years after the closing of the financing. On December 18, 2018, the Company issued 78,625 shares at $0.20 per share for an aggregate amount of $15,725 in respect of future consulting services to be rendered up from January 1, 2019 to December 31, 2019. On December 19, 2018, the Company issued an aggregate of 605,585 units at a price of $0.20 per unit. The total proceeds consist of $95,000 which was previously recorded as a share subscription received on the balance sheet with the remaining gross proceed of $26,117 received in 2018. Each unit comprises one share and one non-transferable common stock share purchase warrant. Each warrant entitles the holder to acquire one additional share of common stock at a price of $0.20 per share until December 19, 2020. On December 19, 2018, the Company issued an aggregate of 500,000 units at a price of $0.20 per unit for total proceeds of $100,000. Each unit comprises one share and one non-transferable common stock share purchase warrant. Each warrant entitles the holder to acquire of $0.20 per share until December 19, 2020. On March 4, 2019, the Company issued an aggregate of 1,252,000 common shares at a price of $0.20 per share for gross proceeds of $250,400. On March 4, 2019, the Company issued 50,000 shares at $0.20 per share for an aggregate amount of $10,000, for proceeds received in previous year. On March 4, 2019, an employee exercised 500,000 options and accordingly received 500,000 common shares at an exercise price of $0.01 per share for aggregate consideration of $5,000. As at September 30, 2019, the Company has $936,000 127,240,587 common shares (December 31, 2018 - 124,063,122) issued and outstanding. Warrants A summary of warrants as at September 30, 2019 and December 31, 2018 is as follows: Warrant Outstanding Weighted Average Number of warrant Exercise Price Balance, December 31, 2018 5,186,835 $ 0.20 Granted 2,075,985 0.20 Expired (1,693,750 ) 0.20 Balance, September 30, 2019 5,569,070 $ 0.20 Warrant Outstanding Weighted Average Number of warrant Exercise Price Balance, December 31, 2017 1,693,750 $ 0.20 Granted 2,387,500 0.20 Balance, September 30, 2018 4,081,250 $ 0.20 Number Outstanding Weighted Average Exercise Price Expiry Date Weighted Average Remaining Life 2,300,000 $0.20 September 7, 2020 0.94 87,500 $0.20 September 17, 2021 1.97 1,105,585 $0.20 December 19, 2020 1.22 618,985 $0.20 April 12, 2021 1.53 1,302,000 $ March 4, 2021 1.43 120,000 $ 0.20 July 19, 2021 1.80 35,000 $ 0.20 July 30, 2021 1.83 5,569,070 $ 1.22 Preferred Shares The Company has authorized 20,000,000 preferred shares at a par value of $0.001 per share. No preferred shares have been issued by the Company and accordingly none are outstanding. Stock Options On March 7, 2016 the Company granted a total of 75,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. of $163 (2018: $811) for such options. On May 5, 2016 the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for ten years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. $636 (2018: $1,701) for such options. On June 6, 2016 the Company granted a total of 800,000 stock options to a consultant. The stock options are exercisable at the exercise price of $0.20 per share and may be exercised for five years. 480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years following June 6, 2016. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant 626,667 $9,242 (2018: $20,268) for such options. On November 1, 2016, the Company granted a total of 360,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One half of the options will vest immediately and one-half shall vest on the on the first anniversary date of grant provided the grantee remains a board member of the Company or its subsidiaries. The options were valued based on the Black Scholes model. On May 31, 2017, the Company granted a total of 875,000 stock options to six employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. $18,598 (2018: $41,755) for such options. On July 2, 2017, the Company granted a total of 150,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the grant date provided the provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. $3,426 (2018: $7,705) for such options. On July 12, 2017, the Company granted a total of 260,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for ten years. 50,000 options vested on grant date. Off the remaining 210,000, one third of the options will vest on each of the first, second and third anniversaries of the grant date provided the employee remains a consultant of the Company or its subsidiaries. $5,168 (2018: $10,662) for such options. On February 13, 2018, the Company granted a total of 231,250 stock options to a consultant. The stock options vest immediately and are exercisable at an exercise price of $0.20 per share and may be exercised over five years. (2018: $26,422) for such options. On June 22, 2018, the Company granted a total of 4,100,000 stock options to a group of employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant, namely June 22, 2019, June 22, 2020 and June 22, 2021 provided the employees remains an employee of the Company or its subsidiaries. $208,638 (2018: $95,589) for such options. On June 22, 2018, the Company granted a total of 1,500,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One quarter of the options will vest immediately. The remaining 1,125,000 options will vest in equal amounts on each of June 22, 2019, June 22, 2020 and June 22, 2021 provided the employee remains an employee of the Company or its subsidiaries. $57,002 (2018; $78,476) for such options. On June 22, 2018, the Company granted a total of 200,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of June 22, 2019, June 22, 2020 and June 22, 2021. The options were valued based on the Black Scholes model. $9,593 (2018: $4,544) for such options. On June 22, 2018, the Company granted a total of 4,000,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One quarter of the options vest on the date of grant, and a further quarter will vest on each of June 22, 2019, June 22, 2020 and June 22, 2021. $143,890 (2018: $207,432) for such options. On June 22, 2018, the Company granted a total of 4,600,000 stock options to a group of employees, consultants and directors. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. The options vest immediately on grant date. The options were valued based on the Black Scholes model. (2018: $640,896) for such options. On July 18, 2018, the Company granted a total of 360,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for ten years. 150,000 of the options vest on the date of grant, and one third of the options will vest at the end of each year of service as at July 18, 2019, 2020 and 2021. The options were valued based on the Black Scholes model. $12,988 (2018: $29,662) for such options. On September 12, 2018, the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for ten years. 30,000 of the options vest on the date of grant, and 40,000 of the options will vest at the end of each year of service as at September 12, 2019, 2020 and 2021. The options were valued based on the Black Scholes model. $8,673 (2018: $5,696) for such options. On September 14, 2018, the Company granted a total of 105,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.20 per share and expired on April 25, 2023. 15,000 options vested at the end of each 7 months of services. The options were valued based on the Black Scholes model. $2,901 (2018: $317) for such options. On November 22, 2018, the Company granted a total of 250,000 stock options to a consultant. The stock options vest immediately and are exercisable at an exercise price of $0.20 per share and may be exercised over seven years. The options were valued based on the Black Scholes model. (2018: $212,893) for such options. On July 19, 2019, the Company granted a total of 125,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.20 per share until July 19, 2026. 65,000 options vested immediately upon issuance and the balance of 60,000 will vest after 6 completed months of consulting service. The options were valued based on the Black Scholes model. For the nine month ended September 30, 2019, the Company recorded stock based compensation of $12,433 for such options. On August 1, 2019, the Company granted a total of 525,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share until August 1, 2026 subject to vesting provisions. One third of the options will vest on each of August 1, 2020, August 1, 2021 and August 1, 2022. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2019, the Company recorded stock based compensation of $8,503 for such options. On September 20, 2019, the Company granted a total of 600,000 stock options to two consultants. The stock options are exercisable at an exercise price of $0.20 per share until September 20, 2024. One-third of the options vest immediately upon issuance and a further one-third vests on each of the first two anniversary dates of the grant. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2019, the Company recorded stock based compensation of $35,096 for such options. The fair value of each option grant is calculated using the following assumptions: 2019 2018 Expected life - year 5—10 5—10 Interest rate 1.49% - 2.86% 1.53% - 2.86% Volatility 61.27% - 96% 65.68% - 94.22% Dividend yield —-% —-% Forfeiture rate —-% —-% Weighted average fair value of options granted $0.13 $0.13 Number of Options Weighted Average Exercise Expire date Price Balance, December 31, 2016 17,345,896 $ 0.05 Granted, on May 31, 2017 875,000 0.200 May 31, 2024 Expired, July 1, 2017 (75,000 ) 0.20 Granted, on July 2, 2017 150,000 0.20 July 2, 2024 Granted, on July 12th, 2017 260,000 0.200 July 12, 2027 Exercised, on September 25, 2017 (150,000 ) 0.01 Balance, December 31, 2017 18,405,896 $ 0.04 Granted, on February 13, 2018 231,250 0.20 February 13, 2023 EExercised, on January 28, 2018 (16,665 ) 0.20 Cancelled, on January 28 2018 (33,335 ) 0.20 Exercised, on March 20, 2018 (481,179 ) 0.001 Granted, on June 22, 2018 14,400,000 0.20 June 22, 2025 Granted, on July 18, 2018 360,000 0.20 July 18, 2028 Exercised, on August 14, 2018 (800,000 ) 0.01 Granted, on September 12, 2018 150,000 0.20 September 12, 2028 Granted, on September 14, 2018 105,000 0.20 April 25, 2023 Expired, on September 28, 2018 (25,000 ) 0.20 Granted, on November 22, 2018 250,000 0.20 November 22, 2025 Granted, on July 19, 2019 125,000 0.20 July 19, 2026 Granted, on August 1, 2019 525,000 0.20 August 1, 2026 Granted, on August 20, 2019 600,000 0.20 August 20, 2026 Balance, December 31, 2018 33,795,967 $ 0.13 Exercised on March 04, 2019 (500,000 ) 0.20 33,295,967 $ 0.13 Outstanding September 30, 2019 Exercisable as at September 30, 2019 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Price Number of Options Exercise Contractual Number of Exercise Contractual Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 2.92 9,750,000 $ 0.01 2.92 0.01 1,924,717 0.01 1.12 1,924,717 0.01 1.12 0.20 150,000 0.20 1.59 150,000 0.20 1.59 0.20 120,000 0.20 2.90 120,000 0.20 2.9 0.20 1,610,000 0.20 2.85 1,610,000 0.20 2.85 0.20 75,000 0.20 2.92 75,000 0.20 2.92 0.20 50,000 0.20 3.15 50,000 0.20 3.15 0.20 100,000 0.20 3.19 100,000 0.20 3.19 0.20 125,000 0.20 3.17 125,000 0.20 3.17 0.20 75,000 0.20 3.44 75,000 0.20 3.44 0.20 150,000 0.20 6.60 150,000 0.20 6.60 0.20 800,000 0.20 1.68 653,334 0.20 1.68 0.20 360,000 0.20 4.09 360,000 0.20 4.09 0.20 850,000 0.20 4.67 570,834 0.20 4.67 0.20 150,000 0.20 0.76 100,000 0.20 0.76 0.20 260,000 0.20 0.78 190,000 0.20 0.78 0.20 231,250 0.20 3.38 231,250 0.20 3.38 0.20 4,100,000 0.20 5.73 1,366,667 0.20 5.73 0.20 1,500,000 0.20 5.74 750,000 0.20 5.74 0.20 200,000 0.20 5.74 66,667 0.20 5.74 0.20 4,000,000 0.20 5.74 2,000,000 0.20 5.74 0.20 4,600,000 0.20 5.74 4,600,000 0.20 5.74 0.20 360,000 0.20 8.81 220,000 0.20 8.81 0.20 105,000 0.20 3.57 15,000 0.20 3.57 0.20 150,000 0.20 8.96 70,000 0.20 8.96 0.20 250,000 0.20 6.15 250,000 0.20 6.15 0.20 125,000 0.20 6.81 65,000 0.20 6.81 0.20 525,000 0.20 6.84 — 0.20 6.84 0.20 600,000 0.20 4.89 200,000 0.20 6.89 33,295,967 $ 0.13 3.42 25,838,469 $ 0.10 3.94 Non-Controlling Interests The Company’s subsidiary, Savicell, granted a third party a warrant certificate to purchase 1,765 common shares of Savicell that initially represented 15% of the underlying common equity of Savicell. In the course of its initial equity issuances up to October 30, 2012 (the “Initial Closing”), Savicell issued a total of 592 ordinary shares at $1,698.97 per share to the non-related third party representing approximately 4.79% of the fully diluted common equity of Savicell for aggregate proceeds of $1,005,795. The Savicell investors are entitled to convert their Savicell shares into common shares of ODT (1:10,625) at a price equal to 80% of the per share pricing of the first completed ODT financing of over $500,000 conducted after July 1, 2012 (the “Financing Price”) provided that for purposes of such conversion, the deemed maximum Financing Price shall be the per share price of the common shares of ODT based on (a) an aggregate ODT equity valuation of $30,000,000; and (b) the number of common shares of ODT outstanding at the time of the financing. Savicell continued its equity issuances following the Initial Closing. As at December 31, 2012, Savicell had issued a total of 684 shares at $1,698.97 per share representing approximately 5.11% of the fully diluted common equity of Savicell for aggregate proceeds of $1,162,192. During the year ended December 31, 2013, Savicell issued a total of 760 shares at $1,700 per share representing approximately 5.68% of the fully diluted common equity of Savicell for aggregate proceeds of $1,292,000. During the year ended December 31, 2014, Savicell issued a total of 183 shares at $1,699 per share representing approximately 1.37% of the fully diluted common equity of Savicell for aggregate proceeds of $310,977. During the year ended December 31, 2015, Savicell issued a total of 417 shares at $1,700 per share to third parties for aggregate proceeds of $709,087. As at December 31, 2015, Savicell also issued 516 shares at $1,700 to ODT, which of $532,084 has not been received as at December 31, 2015. In addition, Savicell investors exchanged 588 Savicell shares for 6,248,672 of ODT common shares with ODT receiving the Savicell shares so exchanged. During the year ended December 31, 2016, Savicell investors exchanged 1,132 Savicell shares for 12,026,654 of ODT common shares with ODT receiving the Savicell shares so exchanged. As at December 31, 2016, Savicell received $1,786,656 from ODT and issued 1,051 shares to ODT in return. During the year ended December 31, 2017, Savicell investors exchanged 27 Savicell shares for 288,830 of ODT common shares with ODT receiving the Savicell shares so exchanged. Savicell issued 387 shares to settle inter-company debts with ODT. During the year ended December 31, 2018, Savicell issued 1,467 shares to settle inter-company debts with ODT. The Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 87.81%, 10.43% and 1.76%, respectively. During the nine months ended September 30, 2019, Savicell investors exchanged 89 Savicell shares for 756,480 of ODT Common Shares with ODT receiving the Savicell shares so exchanged. As at September 30, 2019, The Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 87.87%, 10.37% and 1.76%, respectively (December 31, 2018 – 87.81%, 10.43% and 1.76%). Savicell’s Common Shares Number Amount in NIS of Shares Balance, December 31, 2017 15,450 6,264,821 Shares issued to settle inter-company debts 1,467 2,494,219 Balance, December 31, 2018 16,917 8,759,040 Shares issued to settle inter-company debts 89 151,296 Balance, September 30, 2019 17,006 8,910,336 As the exercise price inherent in the warrant certificate to purchase 1,765 common shares of Savicell is at nominal value, the warrant certificate is valued at the price of the subsequent equity issuance by Savicell ($1,698.97 per share) and the related common shares are considered to be issued and outstanding.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Loss Per Share [Text Block]	Note 11 – Loss per Share We present both basic and diluted income per share on the face of our condensed interim consolidated statements of operations. Basic and diluted income per share are calculated as follows: Three months ended Three months ended September 30, 2019 September 30, 2018 Net loss $ (675,945 ) $ (594,239 ) Weighted average common shares outstanding: Basic and diluted 127,240,587 121,619,939 Net loss per common share: Basic and diluted $ (0.00 ) $ (0.00 ) Nine months ended Nine months ended September 30, 2019 September 30, 2018 Net loss $ ( ) $ ( ) Weighted average common shares outstanding: Basic and diluted 126,340,628 120,136,973 Net loss per common share: Basic and diluted $ (0.01 ) $ (0.02 ) Certain stock options whose terms and conditions are described in Note 10, "Stock Options" could potentially dilute basic and dilute loss per share in the future, but were not included in the computation of diluted loss per share because to do so would have been anti-dilutive. Those anti-dilutive options are as follows. 2019 2018 Anti-dilutive options 11,674,717 12,174,716

Commitments And Guarantees

Commitments And Guarantees	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Commitments And Guarantees [Text Block]	Note 12 – Commitments and Guarantees The Company was not a guarantor to any parties as at . 1. On September 11, 2012, ODT signed an employment agreement with Giora Davidovits, its chief executive officer and President, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief executive officer, the Company will provide Mr. Davidovits an annual salary of $250,000 together with other benefits and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2022 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Giora Davidovits options to purchase 3,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 2. On October 30, 2012, ODT and Savicell signed an employment agreement with Eyal Davidovits, its chief operating officer, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief operating officer, the Company will provide Mr. Davidovits an annual salary of $120,180 (NIS 432,000), together with other fringe benefits including those related to the use of an automobile, health insurance, contributions to government run retirement programs and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2022 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Eyal Davidovits options to purchase 2,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 3. On July 20, 2015, the Company signed an operating lease agreement to lease offices for a period ending July 31, 2018 with an option to renew the lease for an additional period of 2 years. On August 3, 2018, the lease was renewed for an additional two years. The monthly lease expense is $3,372 (NIS 12,121). On July 1, 2018, the Company signed an operating lease agreement for additional office space for a period ending May 31, 2019 with an option to renew the lease for an additional period of 2 years. The monthly lease expense is $1,959 (NIS 7,032). Future minimum lease commitment under the operating lease agreement is approximately $73,863 (NIS 265,168). The Company pledged a bank deposit which is used as a bank guarantee at an amount of $21,875 (NIS 78,531) to secure its payments under the lease agreement. The minimum future payments for the above commitments are as follows: Consulting fee and Year Salaries Office rent Total 2019 $ 277,635 14,207 $ 291,842 2020 370,180 45,724 415,904 2021 370,180 11,759 381,939 2022 246,787 — 246,787 2023 — — — Total $ 1,264,782 $ 71,690 $ 1,336,472

Geographic Information

Geographic Information	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Geographic Information [Text Block]	Note 13 – Geographic Information The Company’s head office is located in the United States (“US”). The operations of the Company are primarily in two geographic areas: the US and Israel. A summary of geographical information for the Company’s long-lived assets are as follows: Period ended September 30, 2019 US Israel Total Long-lived assets $ — $ 35,629 $ 35,629 Year ended December 31, 2018 US Israel Total Long-lived assets $ - $ 45,274 $ 45,274

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Subsequent Events [Text Block]	Note 14 – Subsequent Events 1. On October 25, 2019, the Company raised capital investments totalling $1,012,000 which represent a total share issuance of 5,600,0000 units at an issuance price of $0.20 each. Each unit comprises one common share and one non-transferable common stock share purchase warrant. Each warrant entitles the holder to acquire one additional share of common stock at a price of $0.20 per share for two years. 2. On November 1, 2019, the Company raised capital investments totalling $50,000 which represent a total of 250,000 units at an issuance price of $0.20 each. Each unit comprises one common share and one non-transferable common stock share purchase warrant. Each warrant entitles the holder to acquire one additional share of common stock at a price of $0.20 per share for two years. As of November 25, 2019, these shares have yet to be issued to investors. 3. On November 5, 2019, the Company raised capital investments totalling $200,000 which represent a total of 1,000,000 units at an issuance price of $0.20 each. Each unit comprises one common share and one non-transferable common stock share purchase warrant. Each warrant entitles the holder to acquire one additional share of common stock at a price of $0.20 per share for two years. As of November 25, 2019, these shares have yet to be issued to investors. 4. On November 10, 2019, the Company granted a total of 50,000 .

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Basis of Presentation [Policy Text Block]	a) Basis of Presentation These condensed interim consolidated financial statements have been prepared for interim financial reporting in conformity with generally accepted accounting principles in the United States of America ("US GAAP"), and are expressed in United States dollars, unless otherwise noted. All adjustments considered necessary for a fair presentation of financial position, results of operations and cash flows for the nine months ended September 30, 2019 have been included.
Principles of Consolidation [Policy Text Block]	b) Principles of Consolidation These condensed interim consolidated financial statements include the accounts of the Company and its 87.87% (December 31, 2018 – 87.81%) interest in Savicell. All significant intercompany accounts and transactions have been eliminated upon consolidation.
Use of Estimates [Policy Text Block]	c) Use of Estimates The preparation of condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred tax assets and assessment of lease.
Foreign Currency Translation [Policy Text Block]	d) Foreign Currency Translation The Company’s functional currency is the U.S. dollar. The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). Transactions in other currencies are recorded in U.S. dollars at the rates of exchange prevailing when the transactions occur. Monetary assets and liabilities denominated in other currencies are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates. Exchange gains and losses are recorded in the statements of operations. Results of operations are translated into the Company’s presentation currency, U.S. dollars, at an appropriate average rate of exchange during the year. Net assets and liabilities are translated to U.S. dollars for presentation purposes at rates of exchange in effect at the end of the period. Gains or losses arising on translation are recognized in other comprehensive income (loss) as foreign currency translation adjustments.
Cash and Cash Equivalents [Policy Text Block]	e) Cash and Cash Equivalents Cash and cash equivalents consist entirely of readily available cash balances. There were no cash equivalents as of September 30, 2019 and December 31, 2018.
Restricted cash [Policy Text Block]	f) Restricted cash Restricted cash mainly consists of cash reserve and security deposits required for rental office.
Share-based Payment Arrangement, Director [Policy Text Block]	g) Stock-based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation-Stock Compensation ("ASC 718"). ASC 718 requires all stock-based payments to employees and non-employees including grants of stock options, to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock.
Stock for Services [Policy Text Block]	h) Stock for Services The Company periodically issues common stock, warrants and common stock options to consultants for various services. Costs of these transactions are measured at the fair value of the service received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete.
Income Taxes [Policy Text Block]	i) Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, deferred tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply when the asset is realized or the liability is settled. The effect of a change in income tax rates on deferred tax liabilities and assets is recognized in income in the period in which the change occurs. Deferred tax assets are recognized to the extent that they are considered more likely than not to be realized. Per FASB ASC 740 "Income taxes" under the liability method, it is the Company's policy to provide for uncertain tax positions and the related interest and penalties based upon management's assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At September 30, 2019, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company's effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company's tax positions are recorded as Interest Expense.
Comprehensive Income (Loss) [Policy Text Block]	j) Comprehensive Income (Loss) The Company accounts for comprehensive income under the provisions of ASC Topic 220-10, Comprehensive Income - Overall, which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statements of Operations and Comprehensive Loss.
Earnings (Loss) Per Share [Policy Text Block]	k) Earnings (Loss) Per Share Basic loss per share is computed on the basis of the weighted average number of common shares outstanding during each period. Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the three and nine months ended September 30, 2019 and 2018 because the inclusion of such underlying shares would have had an anti-dilutive effect.
Financial Instruments and Fair Value of Financial Instruments [Policy Text Block]	l) Financial Instruments and Fair Value of Financial Instruments Fair Value of Financial Instruments - the Company adopted SFAS ASC 820-10-50, "Fair Value Measurements". This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: • Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. • Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at September 30, 2019, the fair value of cash and cash equivalents was measured using Level 1 inputs, and the fair value of convertible debentures was measured using Level 2 inputs. The Company's financial instruments are cash and cash equivalents, restricted cash, accounts payable, accrued liabilities, promissory note, convertible debentures and convertible loans. The recorded values of our financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Research and Development Expenses [Policy Text Block]	m) Research and Development Expenses In the quarter ended September 30, 2019, all research and development costs are charged to expense as incurred. The majority of these costs are in-house expenses related to consulting fees, materials, salaries of employees working on the R&D projects, rent and legal expenses related to patents. A breakdown of the R&D costs is as follows: Nine months Nine months Three months Three months ended September 30, ended September 30, ended September 30, ended September 30, 2019 2018 2019 2018 Research and Development $ $ $ $ Expenses Consulting fees 35,648 20,069 11,839 5,169 Legal fees 17,918 12,993 4,083 4,686 Office and Miscellaneous Expense 5,549 10,390 1,374 3,444 Payroll expense 533,381 578,825 220,466 191,187 R&D materials and supplies 59,076 20,348 16,211 4,022 Rent 4,291 27,229 2,254 9,732 Share-based compensation 538,054 1,184,096 150,437 230,948 Total 1,193,917 1,853,950 406,664 449,188 Savicell’s financing commitment related to the License and Research Funding Agreement (as defined in Note 4 below) entered into with Ramot at Tel Aviv University was completely fulfilled by December 31, 2015.
Fixed Assets [Policy Text Block]	n) Fixed Assets The depreciation rates applicable to each category of fixed assets are as follows: Class of Properties Depreciation Rate Furniture and Fixtures 15-year; straight-line basis Computer Equipment 3 to 4-year; straight-line basis Lab Equipment 3 to 15-year; straight-line basis
Convertible Debentures [Policy Text Block]	o) Convertible Debentures
Convertible Loans [Policy Text Block]	p) Convertible Loans Convertible loans are accounted for in accordance with ASC 470-20. The Company has determined that the embedded conversion options in the convertible loans are not required to be separately accounted for as a derivative under GAAP.
Modifications to Debt [Policy Text Block]	q) Modifications to Debt The Company evaluates any modifications to its debt in accordance with the applicable guidance in ASC 470-50, Debt-Modifications and Extinguishments. If the debt instruments are substantially modified, the modification is accounted for in the same manner as a debt extinguishment (i.e., a major modification) and the fees paid are recognized as expense at the time of the modification. Otherwise, such fees are deferred and amortized as an adjustment of interest expense over the remaining term of the modified debt instrument using the interest method.
Recently Adopted Accounting Pronouncements [Policy Text Block]	r) Recently Adopted Accounting Pronouncements In July 2017, the FASB issued ASU 2017-11“Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception” (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered, and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to Common Stock holders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company has early adopted the methodologies prescribed by this ASU for the year ended December 31, 2018 and there is no material impact on the Company’s condensed interim consolidated financial statements. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases. For entities that early adopted Topic 842, the amendments are effective upon issuance of ASU 2018-10, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. ASU 2018-10 will be effective for use for fiscal years beginning after December 15, 2018. The Company has adopted the methodologies prescribed by this ASU on January 1, 2019 and there is no material impact on the Company’s condensed interim consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. These amendments expand the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity-Equity-Based Payments to Non-Employees. This standard is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company has adopted the methodologies prescribed by this ASU on January 1, 2019 and there is no material impact on the Company’s condensed interim consolidated financial statements. In February 2016, the Financial Accounting Standards Board ("FASB") issued ASC 842 which requires lessees to recognize a right-of-use ("ROU") asset and lease liability on the balance sheet for virtually all leases. From a lessee perspective, ASC 842 retains a dual model requiring leases to be classified as either operating or finance leases for the income statement. Operating leases will result in straight-line expense, and financing leases will have a front-loaded expense pattern with an interest expense component. On January 1, 2019, the Company adopted ASC 842 and all related amendments using the prospective transition approach. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. Adoption of the new standard resulted in the recording of lease ROU assets and lease liabilities of approximately $90,146 as of January 1, 2019.
Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]	s) Recently Issued Accounting Pronouncements Not Yet Adopted In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. For all entities, amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact this guidance will have on the condensed interim consolidated financial statements, if any.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Schedule of Research and Development Costs [Table Text Block]	Nine months Nine months Three months Three months ended September 30, ended September 30, ended September 30, ended September 30, 2019 2018 2019 2018 Research and Development $ $ $ $ Expenses Consulting fees 35,648 20,069 11,839 5,169 Legal fees 17,918 12,993 4,083 4,686 Office and Miscellaneous Expense 5,549 10,390 1,374 3,444 Payroll expense 533,381 578,825 220,466 191,187 R&D materials and supplies 59,076 20,348 16,211 4,022 Rent 4,291 27,229 2,254 9,732 Share-based compensation 538,054 1,184,096 150,437 230,948 Total 1,193,917 1,853,950 406,664 449,188
Schedule of Properties Estimated Useful life [Table Text Block]	Class of Properties Depreciation Rate Furniture and Fixtures 15-year; straight-line basis Computer Equipment 3 to 4-year; straight-line basis Lab Equipment 3 to 15-year; straight-line basis

Adoption of ASC 842, Leases (Ta

Adoption of ASC 842, Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Schedule Of Right Of Use Assets And Lease Liabilities [Table Text Block]	Right-of-use Asset Lease Liability $ $ Balance, December 31, 2018 — — Adoption of ASC 842 90,146 103,917 Lease expense (26,662 ) — Lease liability expense — 3,318 Lease payments — (42,620 ) Effect of foreign exchange rate changes 6,021 6,679 Balance, September 30, 2019 69,505 71,294 Current — 55,700 Non-current — 15,594
Schedule of remaining expected lease payments under our operating leases [Table Text Block]	Future Lease Payments September 30, 2019 2019 $ 14,207 2020 45,724 2021 11,759 Less: imputed interest (396 ) Present value of operating lease liabilities $ 71,294

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Schedule of Property, Plant and Equipment [Table Text Block]	Furniture and Computer Cost: Fixtures Equipment Lab Equipment Total December 31, 2017 $ 3,871 $ 29,325 $ 49,191 $ 82,387 Additions — 9,933 10,897 20,830 Exchange difference (286 ) (2,580 ) (4,089 ) (6,955 ) December 31, 2018 $ 3,585 $ 36,678 $ 55,999 $ 96,262 Additions — — — — Exchange difference 274 2,802 4,278 7,354 September 30, 2019 $ 3,859 $ 39,480 $ 60,277 $ 103,616 Furniture and Computer Lab Amortization: Fixtures Equipment Equipment Total December 31, 2017 $ 887 $ 19,497 $ 14,868 $ 35,252 Additions 137 6,692 12,311 19,140 Exchange difference (65 ) (1,440 ) (1,899 ) (3,404 ) December 31, 2018 $ 959 $ 24,749 $ 25,280 $ 50,988 Additions 208 3,327 9,286 12,821 Exchange difference ( 615 ) ( 10,289 ) 15,082 4,178 September 30, 2019 $ 552 $ 17,787 $ 49,648 $ 67,987 Furniture and Computer Lab Net Book Value: Fixtures Equipment Equipment Total December 31, 2018 $ 2,626 $ 11,929 $ 30,719 $ 45,274 September 30, 2019 $ 3,307 $ 21,693 $ 10,629 $ 35,629

Convertible Debentures (Tables)

Convertible Debentures (Tables)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Schedule of Debt [Table Text Block]	December 31, 2018 Additions September 30, 2019 Giora Davidovits $ 860,293 $ — $ 860,293 Eyal Davidovits 402,861 — 402,861 Irit Arbel 355,746 — 355,746 Robbie Manis 437,763 — 437,763 Total $ 2,056,663 $ — $ 2,056,663
Schedule of Convertible Debt [Table Text Block]	December 31, 2018 Additions September 30, 2019 Convertible debentures $ 2,056,663 $ — $ 2,056,663 Convertible discount (852,418 ) — (852,418 ) Net convertible debentures 1,204,245 — 1,204,245 Interest accretion 852,418 — 852,418 Exchange difference 4,725 — 4,725 Balance $ 2,061,388 $ — $ 2,061,388

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]	Warrant Outstanding Weighted Average Number of warrant Exercise Price Balance, December 31, 2018 5,186,835 $ 0.20 Granted 2,075,985 0.20 Expired (1,693,750 ) 0.20 Balance, September 30, 2019 5,569,070 $ 0.20 Warrant Outstanding Weighted Average Number of warrant Exercise Price Balance, December 31, 2017 1,693,750 $ 0.20 Granted 2,387,500 0.20 Balance, September 30, 2018 4,081,250 $ 0.20
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number Outstanding Weighted Average Exercise Price Expiry Date Weighted Average Remaining Life 2,300,000 $0.20 September 7, 2020 0.94 87,500 $0.20 September 17, 2021 1.97 1,105,585 $0.20 December 19, 2020 1.22 618,985 $0.20 April 12, 2021 1.53 1,302,000 $ March 4, 2021 1.43 120,000 $ 0.20 July 19, 2021 1.80 35,000 $ 0.20 July 30, 2021 1.83 5,569,070 $ 1.22
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2019 2018 Expected life - year 5—10 5—10 Interest rate 1.49% - 2.86% 1.53% - 2.86% Volatility 61.27% - 96% 65.68% - 94.22% Dividend yield —-% —-% Forfeiture rate —-% —-% Weighted average fair value of options granted $0.13 $0.13
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Average Exercise Expire date Price Balance, December 31, 2016 17,345,896 $ 0.05 Granted, on May 31, 2017 875,000 0.200 May 31, 2024 Expired, July 1, 2017 (75,000 ) 0.20 Granted, on July 2, 2017 150,000 0.20 July 2, 2024 Granted, on July 12th, 2017 260,000 0.200 July 12, 2027 Exercised, on September 25, 2017 (150,000 ) 0.01 Balance, December 31, 2017 18,405,896 $ 0.04 Granted, on February 13, 2018 231,250 0.20 February 13, 2023 EExercised, on January 28, 2018 (16,665 ) 0.20 Cancelled, on January 28 2018 (33,335 ) 0.20 Exercised, on March 20, 2018 (481,179 ) 0.001 Granted, on June 22, 2018 14,400,000 0.20 June 22, 2025 Granted, on July 18, 2018 360,000 0.20 July 18, 2028 Exercised, on August 14, 2018 (800,000 ) 0.01 Granted, on September 12, 2018 150,000 0.20 September 12, 2028 Granted, on September 14, 2018 105,000 0.20 April 25, 2023 Expired, on September 28, 2018 (25,000 ) 0.20 Granted, on November 22, 2018 250,000 0.20 November 22, 2025 Granted, on July 19, 2019 125,000 0.20 July 19, 2026 Granted, on August 1, 2019 525,000 0.20 August 1, 2026 Granted, on August 20, 2019 600,000 0.20 August 20, 2026 Balance, December 31, 2018 33,795,967 $ 0.13 Exercised on March 04, 2019 (500,000 ) 0.20 33,295,967 $ 0.13
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Outstanding September 30, 2019 Exercisable as at September 30, 2019 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Price Number of Options Exercise Contractual Number of Exercise Contractual Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 2.92 9,750,000 $ 0.01 2.92 0.01 1,924,717 0.01 1.12 1,924,717 0.01 1.12 0.20 150,000 0.20 1.59 150,000 0.20 1.59 0.20 120,000 0.20 2.90 120,000 0.20 2.9 0.20 1,610,000 0.20 2.85 1,610,000 0.20 2.85 0.20 75,000 0.20 2.92 75,000 0.20 2.92 0.20 50,000 0.20 3.15 50,000 0.20 3.15 0.20 100,000 0.20 3.19 100,000 0.20 3.19 0.20 125,000 0.20 3.17 125,000 0.20 3.17 0.20 75,000 0.20 3.44 75,000 0.20 3.44 0.20 150,000 0.20 6.60 150,000 0.20 6.60 0.20 800,000 0.20 1.68 653,334 0.20 1.68 0.20 360,000 0.20 4.09 360,000 0.20 4.09 0.20 850,000 0.20 4.67 570,834 0.20 4.67 0.20 150,000 0.20 0.76 100,000 0.20 0.76 0.20 260,000 0.20 0.78 190,000 0.20 0.78 0.20 231,250 0.20 3.38 231,250 0.20 3.38 0.20 4,100,000 0.20 5.73 1,366,667 0.20 5.73 0.20 1,500,000 0.20 5.74 750,000 0.20 5.74 0.20 200,000 0.20 5.74 66,667 0.20 5.74 0.20 4,000,000 0.20 5.74 2,000,000 0.20 5.74 0.20 4,600,000 0.20 5.74 4,600,000 0.20 5.74 0.20 360,000 0.20 8.81 220,000 0.20 8.81 0.20 105,000 0.20 3.57 15,000 0.20 3.57 0.20 150,000 0.20 8.96 70,000 0.20 8.96 0.20 250,000 0.20 6.15 250,000 0.20 6.15 0.20 125,000 0.20 6.81 65,000 0.20 6.81 0.20 525,000 0.20 6.84 — 0.20 6.84 0.20 600,000 0.20 4.89 200,000 0.20 6.89 33,295,967 $ 0.13 3.42 25,838,469 $ 0.10 3.94
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]	Number Amount in NIS of Shares Balance, December 31, 2017 15,450 6,264,821 Shares issued to settle inter-company debts 1,467 2,494,219 Balance, December 31, 2018 16,917 8,759,040 Shares issued to settle inter-company debts 89 151,296 Balance, September 30, 2019 17,006 8,910,336

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended Three months ended September 30, 2019 September 30, 2018 Net loss $ (675,945 ) $ (594,239 ) Weighted average common shares outstanding: Basic and diluted 127,240,587 121,619,939 Net loss per common share: Basic and diluted $ (0.00 ) $ (0.00 ) Nine months ended Nine months ended September 30, 2019 September 30, 2018 Net loss $ ( ) $ ( ) Weighted average common shares outstanding: Basic and diluted 126,340,628 120,136,973 Net loss per common share: Basic and diluted $ (0.01 ) $ (0.02 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2019 2018 Anti-dilutive options 11,674,717 12,174,716

Commitments And Guarantees (Tab

Commitments And Guarantees (Tables)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Consulting fee and Year Salaries Office rent Total 2019 $ 277,635 14,207 $ 291,842 2020 370,180 45,724 415,904 2021 370,180 11,759 381,939 2022 246,787 — 246,787 2023 — — — Total $ 1,264,782 $ 71,690 $ 1,336,472

Geographic Information (Tables)

Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements [Abstract]
Long-lived Assets by Geographic Areas [Table Text Block]	Period ended September 30, 2019 US Israel Total Long-lived assets $ — $ 35,629 $ 35,629 Year ended December 31, 2018 US Israel Total Long-lived assets $ - $ 45,274 $ 45,274

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Ownership percentage of a shareholder	89.00%
Proceeds from disposal of website assets	$ 10
Suppliers payables writeoff	430
Working capital deficit	(305,432)	$ (247,678)
Accumulated deficit	$ 16,884,830	$ 15,255,866
RelationshipScoreboard.com Entertainment Inc [Member]
Equity Method Investment, Ownership Percentage	100.00%
Stock Issued During Period, Shares, Acquisitions	16,000,000

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
ROU assets and lease liabilities after adoption of ASC 842	$ 69,505
Adoption of ASC 842 [Member]
ROU assets and lease liabilities after adoption of ASC 842	$ 69,505	$ 90,146
Savicell Diagnostic Ltd [Member]
Equity Method Investment, Ownership Percentage	87.87%	87.81%

Adoption of ASC 842, Leases (Na

Adoption of ASC 842, Leases (Narrative) (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Leases [Line Items]
Right-of-use Assets	$ 69,505	$ 69,505
Current	55,700	55,700
Non-current	$ 15,594	$ 15,594
Adoption of ASC 842 [Member]
Leases [Line Items]
Operating discount rate	5.00%	5.00%
Operating lease costs	$ 14,544	$ 42,620
Right-of-use Assets	69,505	69,505	$ 90,146
Operating Lease, Liability	71,294	71,294	$ 103,917
Current	55,700	55,700
Non-current	$ 15,594	$ 15,594
Description of rental lease expiry dates		rental lease that has expiry dates within the next 2 years

License and Research Funding _2

License and Research Funding Agreement (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 25, 2012	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and development expense		$ 406,664	$ 449,188	$ 1,193,917	$ 1,853,950
Savicell Diagnostic Ltd [Member]
Payments to acquire in process research and development	$ 1,600,000
Warrants issued, percentage of interest	15.00%
Warrants issued during period, value	$ 2,998,682
Class of warrant or right, grants in period, net of forfeitures	1,765
Warrants issued during period, value per warrant	$ 1,698.97
Research and development expense		$ 406,664	$ 449,188	$ 1,193,917	$ 1,853,950
Savicell Diagnostic Ltd [Member] | Within 5 Business Days [Member]
Payments to acquire in process research and development	81,000
Savicell Diagnostic Ltd [Member] | Before October 2012 [Member]
Payments to acquire in process research and development	359,500
Savicell Diagnostic Ltd [Member] | Before January 3, 2013 [Member]
Payments to acquire in process research and development	359,500
Savicell Diagnostic Ltd [Member] | Before April 3, 2013 [Member]
Payments to acquire in process research and development	$ 400,000

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Convertible Debentures	$ 2,061,388		$ 2,061,388		$ 2,061,388
Directors and officers [Member]
Related Party Transaction, Amounts of Transaction	128,703	$ 98,644	385,649	$ 364,132
Accounts Payable and Accrued Liabilities	220,020		220,020		94,045
Two directors, one consultant, and one key management personnel [Member]
Convertible Debentures	$ 2,061,388		$ 2,061,388		$ 2,061,388

Promissory Note (Narrative) (De

Promissory Note (Narrative) (Details) - Consultant And Former Director [Member] - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Promissory Note [Line Items]
Promissory note issued				$ 50,000
Interest rate	10.00%	10.00%
Threshold Limit of Equity Financing		$ 250,000
Interest incurred	$ 663	2,865
Repayments of promissory note remaining balance		$ 35,000

Convertible Debentures (Narrati

Convertible Debentures (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 15, 2015	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2015
Debt Conversion, Converted Instrument, Amount	$ 852,418	$ 843,266	$ 172,895	$ 188,085
Conversion price per share	$ 0.055	$ 0.20	$ 0.20	$ 0.20
Debt instrument, convertible, beneficial conversion feature		$ 852,418
Amortization of debt discount, effective interest rate		71.00%
Debt instrument, amortized discount		$ 852,418

Convertible Loans (Narrative) (

Convertible Loans (Narrative) (Details) - USD ($)	Mar. 08, 2018	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2015	Apr. 15, 2015
Conversion price per share					$ 0.20	$ 0.20	$ 0.20	$ 0.055
Interest expense		$ 13,535	$ 79,736
Convertible Loan 1 [Member]
Convertible loan face amount	$ 350,000
Maturity term	2 years
Interest rate	10.00%
Conversion price per share	$ 0.20
Proceeds from Issuance of Private Placement	$ 5,000,000
Convertible Loan 2 [Member]
Convertible loan face amount					$ 187,000
Maturity term					2 years
Interest rate					10.00%
Conversion price per share					$ 0.20

Equity (Narrative) (Details)

Equity (Narrative) (Details) - USD ($)	Apr. 12, 2019	Mar. 04, 2019	Sep. 14, 2018	Sep. 12, 2018	Sep. 07, 2018	Jul. 12, 2017	Jul. 02, 2017	Jun. 06, 2016	May 05, 2016	Mar. 07, 2016	Sep. 20, 2019	Aug. 01, 2019	Jul. 19, 2019	Dec. 19, 2018	Nov. 22, 2018	Aug. 27, 2018	Aug. 24, 2018	Jul. 18, 2018	Jun. 22, 2018	Jun. 20, 2018	Apr. 17, 2018	Feb. 13, 2018	May 31, 2017	Nov. 30, 2016	Oct. 30, 2012	Jul. 25, 2012	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 18, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Common Stock, Shares Authorized																											500,000,000		500,000,000
Common Stock, Par or Stated Value Per Share																											$ 0.001		$ 0.001
Number of stock issued in exchange for consulting services		1,252,000																		117,660										78,625
Shares Issued, Price Per Share		$ 0.20																		$ 0.20										$ 0.20
Value of stock issued in exchange for consulting services		$ 250,400																		$ 23,532										$ 15,725
Proceeds from Issuance of Common Stock																											$ 449,654	$ 476,145
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		500,000														800,000	16,665				481,179
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 0.01														$ 0.01	$ 0.20				$ 0.01
Proceeds from Stock Options Exercised		$ 5,000															$ 3,333				$ 4,812
Units Issued During Period, Units	618,985				2,300,000									605,585
Units Issued During Period, Per Unit Amount	$ 0.20				$ 0.20									$ 0.20
Proceeds from units issued	$ 123,797				$ 460,000									$ 95,000
Class of Warrant or Right, Grants in Period, Exercise Price	$ 0.20				$ 0.20									$ 0.20
Gross proceeds from share subscription received														$ 26,117
Share subscriptions received																											$ 936,000
Common Stock, Shares, Issued																											127,240,587		124,063,122
Common Stock, Shares, Outstanding																											127,240,587		124,063,122
Preferred Stock, Shares Authorized																											20,000,000		20,000,000
Preferred Stock, Par or Stated Value Per Share																											$ 0.001		$ 0.001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																											$ 0.13	$ 0.13
Stock-based compensation																											$ 538,054	$ 1,184,096
Exercise price of stock options exercisable																											$ 0.10
Savicell investors [Member]
Class of warrant or right, grants in period, net of forfeitures																										1,765
Common Stock, Conversion Basis																											The Savicell investors are entitled to convert their Savicell shares into common shares of ODT (1:10,625) at a price equal to 80% of the per share pricing of the first completed ODT financing of over $500,000 conducted after July 1, 2012 (the “Financing Price”) provided that for purposes of such conversion, the deemed maximum Financing Price shall be the per share price of the common shares of ODT based on (a) an aggregate ODT equity valuation of $30,000,000; and (b) the number of common shares of ODT outstanding at the time of the financing.
Warrants Issued During Period, Value per Warrant																										$ 1,698.97
Savicells Common Shares
Shares Issued, Price Per Share	$ 0.16
Stock Issued During Period, Shares, New Issues	756,480																								592									183	760	684
Stock Issued During Period, Value, New Issues	$ 6,392																								$ 1,698.97
Sale of Stock, Price Per Share																																		$ 1,699	$ 1,700	$ 1,698.97
Proceeds from Issuance of Common Stock																									$ 1,005,795									$ 310,977	$ 1,292,000	$ 1,162,192
Equity Method Investment, Ownership Percentage																											87.87%		87.81%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners																									4.79%		1.76%		1.76%					1.37%	5.68%	5.11%
Savicells Common Shares [Member]
Stock Issued During Period, Shares, New Issues																																	417
Sale of Stock, Price Per Share																																	$ 1,700
Proceeds from Issuance of Common Stock																																	$ 709,087
Class of warrant or right, grants in period, net of forfeitures																										1,765
Warrants issued, percentage of interest																										15.00%
Shares of subdiary held																																1,051	516
Value of shares of subsidiary not yet received																																	$ 532,084
Shares received in share exhange																											89				27	1,132	588
Shares issued in share exchange																											756,480				288,830	12,026,654	6,248,672
Shares issued to settle inter-company debts (shares)																											89		1,467		387
Payments to Acquire Additional Interest in Subsidiaries																																$ 1,786,656
Savicells Common Shares [Member] | Warrant holder [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners																											10.37%		10.43%
Granted, on March 7, 2016 [Member]
Number of stock options granted										75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 0.20
Stock-based compensation																											$ 163	811
Granted, on May 5, 2016 [Member]
Number of stock options granted									150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.20
Stock-based compensation																											636	1,701
Granted, on June 6, 2016 [Member]
Number of stock options granted								800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 0.20
Stock-based compensation																											$ 9,242	20,268
Terms for vesting of options								480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years following June 6, 2016. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant to the Company
Options, Vested, Number of Shares																											626,667
Granted, on November 1, 2016 [Member]
Number of stock options granted																								360,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																								$ 0.20
Granted, on May 31, 2017 [Member]
Number of stock options granted																							875,000								875,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																							$ 0.20								$ 0.200
Stock-based compensation																											$ 18,598	41,755
Granted, on July 2, 2017 [Member]
Number of stock options granted							150,000																								150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 0.20																								$ 0.20
Stock-based compensation																											3,426	7,705
Granted, on July 12th, 2017 [Member]
Number of stock options granted						260,000																									260,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$ 0.20																									$ 0.200
Stock-based compensation																											5,168	10,662
Terms for vesting of options						50,000 options vested on grant date. Off the remaining 210,000, one third of the options will vest on each of the first, second and third anniversaries of the grant date provided the employee remains a consultant of the Company or its subsidiaries.
Granted on December 19, 2018 [Member]
Units Issued During Period, Units														500,000
Units Issued During Period, Per Unit Amount														$ 0.20
Proceeds from units issued														$ 100,000
Class of Warrant or Right, Grants in Period, Exercise Price														$ 0.20
Granted, on February 13, 2018 [Member]
Number of stock options granted																						231,250							231,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																						$ 0.20							$ 0.20
Stock-based compensation																												26,422
Granted, on June 22, 2018 [Member]
Number of stock options granted																			4,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																			$ 0.20
Stock-based compensation																											208,638	95,589
Granted, on June 22, 2018 - 2 [Member]
Number of stock options granted																			1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																			$ 0.20
Stock-based compensation																											57,002	78,476
Terms for vesting of options																			The remaining 1,125,000 options will vest in equal amounts on each of June 22, 2019, June 22, 2020 and June 22, 2021 provided the employee remains an employee of the Company or its subsidiaries.
Granted, on June 22, 2018 - 3 [Member]
Number of stock options granted																			200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																			$ 0.20
Stock-based compensation																											9,593	4,544
Granted, on June 22, 2018 - 4 [Member]
Number of stock options granted																			4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																			$ 0.20
Stock-based compensation																											143,890	207,432
Granted, on June 22, 2018 - 5 [Member]
Number of stock options granted																			4,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																			$ 0.20
Stock-based compensation																												640,896
Granted, on July 18, 2018 [Member]
Number of stock options granted																		360,000											360,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																		$ 0.20											$ 0.20
Stock-based compensation																											12,988	29,662
Terms for vesting of options																		150,000 of the options vest on the date of grant, and one third of the options will vest at the end of each year of service as at July 18, 2019, 2020 and 2021. The options were valued based on the Black Scholes model.
Granted, on September 12, 2018 [Member]
Number of stock options granted				150,000																									150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 0.20																									$ 0.20
Stock-based compensation																											8,673	5,696
Terms for vesting of options				30,000 of the options vest on the date of grant, and 40,000 of the options will vest at the end of each year of service as at September 12, 2019, 2020 and 2021. The options were valued based on the Black Scholes model.
Granted, on September 14, 2018 [Member]
Number of stock options granted			105,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.20
Stock-based compensation																											2,901	317
Options, Vested, Number of Shares			15,000
Granted, on November 22, 2018 [Member]
Number of stock options granted															250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price															$ 0.20
Stock-based compensation																												$ 212,893
Conversion on March 4, 2019 [Member]
Sale of Stock, Price Per Share		$ 0.20
Shares issued for proceeds received in previous year [Member]
Stock Issued During Period, Shares, New Issues		50,000
Stock Issued During Period, Value, New Issues		$ 10,000
Granted, on July 19, 2019 [Member]
Number of stock options granted													125,000
Stock-based compensation																											$ 12,433
Terms for vesting of options																											The stock options are exercisable at an exercise price of $0.20 per share until July 19, 2026. 65,000 options vested immediately upon issuance and the balance of 60,000 will vest after 6 completed months of consulting service.
Options, Vested, Number of Shares													65,000
Exercise price of stock options exercisable													$ 0.20
Granted, on July 19, 2019 [Member] | Vest after 6 completed months of consulting service [Member]
Options, Vested, Number of Shares													60,000
Granted On August 1 2019 [Member]
Number of stock options granted												525,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price												$ 0.20
Stock-based compensation																											$ 8,503
Terms for vesting of options												The stock options are exercisable at an exercise price of $0.20 per share until August 1, 2026 subject to vesting provisions. One third of the options will vest on each of August 1, 2020, August 1, 2021 and August 1, 2022.
Granted on September 20 2019 [Member]
Number of stock options granted											600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 0.20
Stock-based compensation																											$ 35,096

Commitments And Guarantees (Nar

Commitments And Guarantees (Narrative) (Details)	Sep. 11, 2012USD ($)$ / sharesshares	Jul. 20, 2015ILS (₪)	Jul. 20, 2015USD ($)	Oct. 30, 2012ILS (₪)	Oct. 30, 2012USD ($)$ / sharesshares	Sep. 30, 2019$ / sharesshares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares	Jul. 20, 2015USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares						33,295,967	33,795,967	18,405,896	17,345,896
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares						$ 0.13	$ 0.13	$ 0.04	$ 0.05
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term						3 years 5 months 1 day
Payments under the lease agreement [Member]
Cash Collateral for Borrowed Securities		₪ 78,531								$ 21,875
Office rent [Member]
Lessee, Operating Lease, Renewal Term		2 years								2 years
Operating lease, monthly lease expense		₪ 12,121	$ 3,372
Operating Leases, Future Minimum Payments Due		₪ 265,168								$ 73,863
Office Rent For Additional Office Space [Member]
Lessee, Operating Lease, Renewal Term		2 years								2 years
Operating lease, monthly lease expense		₪ 7,032	$ 1,959
Giora Davidovits [Member]
Officers' Compensation | $	$ 250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares	3,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.01
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	10 years
Eyal Davidovits [Member]
Officers' Compensation				₪ 432,000	$ 120,180
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares					2,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares					$ 0.01
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term				10 years	10 years

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - USD ($)	Apr. 12, 2019	Sep. 07, 2018	Nov. 10, 2019	Nov. 05, 2019	Nov. 01, 2019	Oct. 25, 2019	Dec. 19, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 0.13	$ 0.13
Proceeds from units issued	$ 123,797	$ 460,000					$ 95,000
Units Issued During Period, Units	618,985	2,300,000					605,585
Units Issued During Period, Per Unit Amount	$ 0.20	$ 0.20					$ 0.20
Subsequent Event [Member]
Proceeds from units issued				$ 200,000	$ 50,000	$ 1,012,000
Units Issued During Period, Units				1,000,000	250,000	5,600,000
Units Issued During Period, Per Unit Amount				$ 0.20	$ 0.20	$ 0.20
Exercise price of warrants granted during period				$ 0.20	$ 0.20	$ 0.20
Term Of Warrant				2 years	2 years	2 years
Granted on November 10, 2019 [Member] | Subsequent Event [Member]
Number of stock options granted			50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.20
Terms for vesting of options			The stock options are exercisable at an exercise price of $0.20 per share until November 10, 2026.  One third of the options will vest on each of November 10, 2020, November 10, 2021 and November 10, 2022 provided the employee remains an employee of the Company or its subsidiaries.

Schedule of Research and Develo

Schedule of Research and Development Costs (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and development expense	$ 406,664	$ 449,188	$ 1,193,917	$ 1,853,950
Consulting fees [Member]
Research and development expense	11,839	5,169	35,648	20,069
Legal fees [Member]
Research and development expense	4,083	4,686	17,918	12,993
Office and Miscellaneous Expense [Member]
Research and development expense	1,374	3,444	5,549	10,390
Payroll expense [Member]
Research and development expense	220,466	191,187	533,381	578,825
R&D materials and supplies [Member]
Research and development expense	16,211	4,022	59,076	20,348
Rent [Member]
Research and development expense	2,254	9,732	4,291	27,229
Share-based compensation [Member]
Research and development expense	$ 150,437	$ 230,948	$ 538,054	$ 1,184,096

Schedule of Properties Estimate

Schedule of Properties Estimated Useful life (Details)	9 Months Ended
	Sep. 30, 2019
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	15 years
Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	4 years
Lab Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Lab Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	15 years

Schedule of right of use assets

Schedule of right of use assets and lease liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019
Right-of-use Asset
Lease expense	$ (9,198)	$ 0	$ (26,662)
Balance	69,505		69,505
Lease liability
Lease Liability Expense	975		3,318
Current	55,700		55,700
Non-current	15,594		15,594
Adoption of ASC 842 [Member]
Right-of-use Asset
Adoption of ASC 842			90,146
Lease expense			(26,662)
Effect of foreign exchange rate changes			6,021
Balance	69,505		69,505
Lease liability
Adoption of ASC 842			103,917
Lease Liability Expense			3,318
Lease payments			(42,620)
Effect of foreign exchange rate changes			6,679
Balance	71,294		71,294
Current	55,700		55,700
Non-current	$ 15,594		$ 15,594

Schedule of Remaining Expected

Schedule of Remaining Expected Lease Payments Under Our Operating Lease (Details) - Adoption of ASC 842 [Member] - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Future Lease Payments
2019	$ 14,207
2020	45,724
2021	11,759
Less: imputed interest	(396)
Present value of operating lease liabilities	$ 71,294	$ 103,917

Schedule of Property, Plant and

Schedule of Property, Plant and Equipment (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment, Cost, Beginning Balance	$ 96,262	$ 82,387
Additions	0	20,830
Exchange difference (Cost)	7,354	(6,955)
Property, Plant and Equipment, Cost, Ending Balance	103,616	96,262
Property, Plant and Equipment, Depreciation, Beginning Balance	50,988	35,252
Additions (Depreciation)	12,821	19,140
Exchange difference (Depreciation)	4,178	(3,404)
Property, Plant and Equipment, Depreciation, Ending Balance	67,987	50,988
Property, Plant and Equipment, Net Book Value	35,629	45,274
Furniture and Fixtures [Member]
Property, Plant and Equipment, Cost, Beginning Balance	3,585	3,871
Additions	0	0
Exchange difference (Cost)	274	(286)
Property, Plant and Equipment, Cost, Ending Balance	3,859	3,585
Property, Plant and Equipment, Depreciation, Beginning Balance	959	887
Additions (Depreciation)	208	137
Exchange difference (Depreciation)	(615)	(65)
Property, Plant and Equipment, Depreciation, Ending Balance	552	959
Property, Plant and Equipment, Net Book Value	3,307	2,626
Computer Equipment [Member]
Property, Plant and Equipment, Cost, Beginning Balance	36,678	29,325
Additions	0	9,933
Exchange difference (Cost)	2,802	(2,580)
Property, Plant and Equipment, Cost, Ending Balance	39,480	36,678
Property, Plant and Equipment, Depreciation, Beginning Balance	24,749	19,497
Additions (Depreciation)	3,327	6,692
Exchange difference (Depreciation)	(10,289)	(1,440)
Property, Plant and Equipment, Depreciation, Ending Balance	17,787	24,749
Property, Plant and Equipment, Net Book Value	21,693	11,929
Lab Equipment [Member]
Property, Plant and Equipment, Cost, Beginning Balance	55,999	49,191
Additions	0	10,897
Exchange difference (Cost)	4,278	(4,089)
Property, Plant and Equipment, Cost, Ending Balance	60,277	55,999
Property, Plant and Equipment, Depreciation, Beginning Balance	25,280	14,868
Additions (Depreciation)	9,286	12,311
Exchange difference (Depreciation)	15,082	(1,899)
Property, Plant and Equipment, Depreciation, Ending Balance	49,648	25,280
Property, Plant and Equipment, Net Book Value	$ 10,629	$ 30,719

Schedule of Debt (Details)

Schedule of Debt (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Convertible debentures	$ 2,056,663	$ 2,056,663
Additions	0
Giora Davidovits [Member]
Convertible debentures	860,293	860,293
Additions	0
Eyal Davidovits [Member]
Convertible debentures	402,861	402,861
Additions	0
Irit Arbel [Member]
Convertible debentures	355,746	355,746
Additions	0
Robbie Manis [Member]
Convertible debentures	437,763	$ 437,763
Additions	$ 0

Schedule of Convertible Debt (D

Schedule of Convertible Debt (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Convertible Debenture	$ 2,061,388	$ 2,061,388
Additions	0
Convertible debentures [Member]
Convertible Debenture	2,056,663	2,056,663
Additions	0
Convertible discount [Member]
Convertible Debenture	(852,418)	(852,418)
Additions	0
Net convertible debentures [Member]
Convertible Debenture	1,204,245	1,204,245
Additions	0
Interest accretion [Member]
Convertible Debenture	852,418	852,418
Additions	0
Exchange difference [Member]
Convertible Debenture	4,725	$ 4,725
Additions	$ 0

Schedule of Stockholders' Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Class of Warrant or Right, Outstanding, Beginning of Period	5,186,835	1,693,750
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.20	$ 0.20
Class of Warrant or Right Granted	2,075,985	2,387,500
Class of Warrant or Right Granted Weighted Average Exercise Price	$ 0.20	$ 0.20
Class of Warrant or Right Expired	(1,693,750)
Class Of Warrant Or Right Expired Weighted Average Exercise Price	$ 0.20
Class of Warrant or Right, Outstanding, End of Period	5,569,070	4,081,250
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, End of Period	$ 0.20	$ 0.20

Schedule of Stockholders' Equ_2

Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Number of Outstanding Warrants	5,569,070	5,186,835	4,081,250	1,693,750
Exercise Price	$ 0.20	$ 0.20	$ 0.20	$ 0.20
Remaining Life	1 year 2 months 19 days
Weighted Average Exercise Price One [Member]
Number of Outstanding Warrants	2,300,000
Exercise Price	$ 0.20
Remaining Life	11 months 8 days
Weighted Average Exercise Price Two [Member]
Number of Outstanding Warrants	87,500
Exercise Price	$ 0.20
Remaining Life	1 year 11 months 19 days
Weighted Average Exercise Price Three [Member]
Number of Outstanding Warrants	1,105,585
Exercise Price	$ 0.20
Remaining Life	1 year 2 months 19 days
Weighted Average Exercise Price Four [Member]
Number of Outstanding Warrants	618,985
Exercise Price	$ 0.20
Remaining Life	1 year 6 months 10 days
Weighted Average Exercise Price Five [Member]
Number of Outstanding Warrants	1,302,000
Exercise Price	$ 0.20
Remaining Life	1 year 5 months 4 days
Weighted Average Exercise Price Six [Member]
Number of Outstanding Warrants	120,000
Exercise Price	$ 0.20
Remaining Life	1 year 9 months 18 days
Weighted Average Exercise Price Seven [Member]
Number of Outstanding Warrants	35,000
Exercise Price	$ 0.20
Remaining Life	1 year 9 months 29 days

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Volatility, Minimum	61.27%	65.68%
Volatility, Maximum	96.00%	94.22%
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Weighted average fair value of options granted	$ 0.13	$ 0.13
Minimum [Member]
Expected life year	5 years	5 years
Interest rate	1.49%	1.53%
Maximum [Member]
Expected life year	10 years	10 years
Interest rate	2.86%	2.86%

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	Mar. 04, 2019	Sep. 12, 2018	Jul. 12, 2017	Jul. 02, 2017	Aug. 27, 2018	Aug. 24, 2018	Jul. 18, 2018	Apr. 17, 2018	Feb. 13, 2018	May 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period											33,795,967	18,405,896	18,405,896	17,345,896
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period											$ 0.13	$ 0.04	$ 0.04	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 0.13	$ 0.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(500,000)				(800,000)	(16,665)		(481,179)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 0.01				$ 0.01	$ 0.20		$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period											33,295,967		33,795,967	18,405,896
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period											$ 0.13		$ 0.13	$ 0.04
Granted, on May 31, 2017 [Member]
Number of stock options granted										875,000				875,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 0.20				$ 0.200
Expired, July 1, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period														(75,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price														$ 0.20
Granted, on July 2, 2017 [Member]
Number of stock options granted				150,000										150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 0.20										$ 0.20
Granted, on July 12th, 2017 [Member]
Number of stock options granted			260,000											260,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.20											$ 0.200
Exercised, on September 25, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period														(150,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price														$ 0.01
Granted, on February 13, 2018 [Member]
Number of stock options granted									231,250				231,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.20				$ 0.20
Exercised, on January 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period													(16,665)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price													$ 0.20
Cancelled, on January 28 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period													(33,335)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price													$ 0.20
Exercised, on March 20, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period													(481,179)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price													$ 0.001
Granted, on June 22, 2018 [Member]
Number of stock options granted													14,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price													$ 0.20
Granted, on July 18, 2018 [Member]
Number of stock options granted							360,000						360,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 0.20						$ 0.20
Exercised, on August 14, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period													(800,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price													$ 0.01
Granted, on September 12, 2018 [Member]
Number of stock options granted		150,000											150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.20											$ 0.20
Granted, on September 14, 2018 [Member]
Number of stock options granted													105,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price													$ 0.20
Expired, on September 28, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period													(25,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price													$ 0.20
Granted, on November 22, 2018 [Member]
Number of stock options granted													250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price													$ 0.20
Exercised on March 04, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											(500,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price											$ 0.20
Granted, on July 19, 2019 [Member]
Number of stock options granted											125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 0.20
Granted, on August 1, 2019 [Member]
Number of stock options granted											525,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 0.20
Granted, on August 20, 2019 [Member]
Number of stock options granted											600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 0.20

Schedule of Disclosure of Share

Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	33,295,967	33,795,967	18,405,896	17,345,896
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.13	$ 0.13	$ 0.04	$ 0.05
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 5 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	25,838,469
Exercise price of stock options exercisable	$ 0.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 11 months 8 days
Range 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	9,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.01
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	2 years 11 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	9,750,000
Exercise price of stock options exercisable	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 11 months 1 day
Range 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,924,717
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.01
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	1 year 1 month 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,924,717
Exercise price of stock options exercisable	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 1 month 13 days
Range 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	1 year 7 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	150,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 7 months 2 days
Range 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	120,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	2 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	120,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 10 months 24 days
Range 5 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,610,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	2 years 10 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,610,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 10 months 6 days
Range 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	2 years 11 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	75,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 11 months 1 day
Range 7 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 1 month 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	50,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 1 month 24 days
Range 8 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 2 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	100,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 2 months 8 days
Range 9 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 2 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	125,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 2 months 1 day
Range 10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 5 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	75,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 5 months 8 days
Range 11 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	6 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	150,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 7 months 6 days
Range 12 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	1 year 8 months 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	653,334
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 8 months 4 days
Range 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	360,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	4 years 1 month 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	360,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 1 month 2 days
Range 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	850,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	4 years 8 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	570,834
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 8 months 1 day
Range 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 months 3 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	100,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	9 months 3 days
Range 16 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	260,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 months 10 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	190,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	9 months 10 days
Range 17 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	231,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 4 months 17 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	231,250
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 4 months 17 days
Range 18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 8 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,366,667
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 8 months 23 days
Range 19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	750,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Range 20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	66,667
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Range 21 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	2,000,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Range 22 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,600,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 8 months 26 days
Range 23 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	360,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	8 years 9 months 21 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	220,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 9 months 21 days
Range 24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	105,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 6 months 25 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	15,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 6 months 25 days
Range 25 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	8 years 11 months 15 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	70,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	8 years 11 months 15 days
Range 26 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	6 years 1 month 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	250,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 1 month 24 days
Range 27 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	6 years 9 months 21 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	65,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 9 months 21 days
Range 28 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	525,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	6 years 10 months 2 days
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 10 months 2 days
Range 29 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	4 years 10 months 20 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	200,000
Exercise price of stock options exercisable	$ 0.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	6 years 10 months 20 days

Schedule of Consolidation, Less

Schedule of Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2019ILS (₪)shares	Sep. 30, 2019USD ($)shares	Dec. 31, 2018ILS (₪)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017ILS (₪)shares
Beginning Balance | $		$ (2,710,763)
Ending Balance | $		$ (2,632,499)		$ (2,710,763)
Savicells Common Shares [Member]
Beginning Balance (shares) | shares	16,917	16,917	15,450	15,450
Beginning Balance | ₪	₪ 8,759,040		₪ 6,264,821
Shares issued to settle inter-company debts (shares) | shares	89	89	1,467	1,467	387
Shares issued to settle inter-company debts | ₪	₪ 151,296		₪ 2,494,219
Ending Balance (shares) | shares	17,006	17,006	16,917	16,917	15,450
Ending Balance | ₪	₪ 8,910,336		₪ 8,759,040		₪ 6,264,821

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss	$ (675,945)	$ (594,239)	$ (1,787,580)	$ (2,581,409)
Weighted average common shares outstanding:
Basic and diluted	127,240,587	121,619,939	126,340,628	120,136,973
Net loss per common share:
Basic and diluted	$ 0	$ 0	$ (0.01)	$ (0.02)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Anti-dilutive options	11,674,717	12,174,716

Schedule of minimum future paym

Schedule of minimum future payments (Details)	Sep. 30, 2019USD ($)
2019	$ 291,842
2020	415,904
2021	381,939
2022	246,787
2023	0
Total	1,336,472
Consulting fee and Salaries [Member]
2019	277,635
2020	370,180
2021	370,180
2022	246,787
2023	0
Total	1,264,782
Office rent [Member]
2019	14,207
2020	45,724
2021	11,759
2022	0
2023	0
Total	$ 71,690

Schedule of Long-lived Assets b

Schedule of Long-lived Assets by Geographic Areas (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Long-lived assets	$ 35,629	$ 45,274
US [Member]
Long-lived assets	0	0
Israel [Member]
Long-lived assets	$ 35,629	$ 45,274